Grace Research, LLC | Shreveport, LA

Research site

(Unclaimed)

Location

1811 East Bert Kouns, Suite 100, Shreveport, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

BI 456906

TQJ230

BI 690517

Survodutide

Triglyceride

Lorundrostat

Obicetrapib

sodium

Bococizumab

Parent organization

This site is a part of Grace Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 14 total trials

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: Empagliflozin

Drug: BI 690517

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and eleva...

Active, not recruiting

Cardiovascular Disease and Lipoprotein(a)

Drug: TQJ230

Drug: Placebo

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting

Coronary Heart Disease (CHD)

Drug: Evolocumab

Drug: Placebo

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Active, not recruiting

Hypertension

Drug: Placebo

Drug: lorundrostat Dose 2

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg